Qurient Co. Ltd

Qurient Co., Ltd. is a biotechnology company that researches and develops drugs for unmet medical needs in Korea and internationally. Its pipeline includes Q301, a topical 5LO inhibitor in Phase II trials for atopic dermatitis; Telacebec (Q203), a Cyt bc1 inhibitor in Phase II for mycobacterial infections such as tuberculosis/non-TBM; Adrixetinib (Q702), an Axl/Mer/CSF1R inhibitor that completed Phase I for solid tumors; and Q901, a selective CDK7 inhibitor in Phase I for solid tumors. The company was formerly known as Quro Science Inc. and changed its name to Qurient Co., Ltd. in October 2011. Founded in 2008, it is headquartered in Seongnam-si, South Korea.